CHOP, in collaboration with Onyx Therapeutics, Inc., is
conducting a study for children and young adults up to 21 years old, with relapsed
or refractory acute lymphoblastic leukemia. This clinical trial is adding the
study drug, Carfilzomib, to a standard relapse chemotherapy regimen. For more
information about this study, including specific eligibility criteria, please
visit clinicaltrials.gov and search for "NCT02303821". To hear more
about this and other available trails or get any questions answered please
contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.